Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

about

Peptide inhibition of the SETD6 methyltransferase catalytic activity.Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors.Peptide Mimetics: Fast-Forward Look.

P2860

Q50052960-9D0FB13C-87C0-42C2-BBA7-9FC4EDFB0606 Q52680710-594134D3-807B-45A7-8B2E-E3C190D76C47 Q53813992-E912EF1F-11F9-4820-98C8-6E9C02A22127

P2860

Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

Item

http://www.wikidata.org/entity/Q47980008

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

@en

Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

@nl

type

Item

label

Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

@en

Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

@nl

prefLabel

Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

@en

Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

@nl

P1476

Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

@en

P2093

Dominic N McBrayer

http://www.w3.org/2001/XMLSchema#string

P2860

Mammalian pancreatic preproglucagon contains three glucagon-related peptides

Synaptotagmin-7 phosphorylation mediates GLP-1-dependent potentiation of insulin secretion from β-cells

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals.

The role of incretins in glucose homeostasis and diabetes treatment.

Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.

Self-assembling glucagon-like peptide 1-mimetic peptide amphiphiles for enhanced activity and proliferation of insulin-secreting cells

P304

292-299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/DDR.21404

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yftah Tal-Gan

Dominic McBrayer

P577

2017-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28786125

http://www.w3.org/2001/XMLSchema#string

P932

5602594

http://www.w3.org/2001/XMLSchema#string

Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

about

P2860

P2860

Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932